Robert J. Cardnell
The University of Texas MD Anderson Cancer Center(US)The University of Texas MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Lung Cancer Research Studies, Phagocytosis and Immune Regulation, Pancreatic and Hepatic Oncology Research, Neuroendocrine Tumor Research Advances, Microtubule and mitosis dynamics
Most-Cited Works
- → An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance(2012)1,115 cited
- → Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities(2021)886 cited
- → Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer(2017)224 cited
- → Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC(2019)119 cited
- → Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies(2017)92 cited
- → Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer